CONCLUSION
Cemi, cHL, PTCL, DLBCL
CHL
Isa + Cemi had a manageable safety profile. Limited clinical efficacy was observed in patients with cHL who had prior anti‐PD‐1/PD‐L1 exposure, as well as in those who did not. However, we did not observe a synergistic effect of Isa in combination with Cemi in patients with cHL, DLBCL, or PTCL.